Regulatory agency authorizes increase in the weekly dose of the drug Poviztra to 7.2 mg against obesity

Agência Nacional of Vigilância Sanitária approved the update of the dosage of the drug Poviztra, authorizing the administration of a maintenance dose of up to 7.2 mg per week. The government decision, published in Diário Oficial of União, changes the treatment guidelines for adult patients diagnosed with obesity or overweight associated with comorbidities. The regulatory adjustment aims to serve individuals who did not show a sufficient clinical response to the previous maximum dosage, set at 2.4 mg weekly. The release follows safety protocols established by health authorities and reflects the advancement of injectable therapies in the country.
The drug, developed based on the active ingredient semaglutide, acts as an agonist of the glucagon-like peptide-1 receptor, known by the acronym GLP-1. Poviztra is registered on the national market as a clone of Wegovy, a reference product manufactured by the Danish pharmaceutical company Novo Nordisk. The new version is being sold through a strategic partnership with the Brazilian company Eurofarma. Pharmacological treatment requires continuous monitoring and remains strictly associated with a dietary re-education program with a calorie deficit and regular physical activity.
Critérios doctors to prescribe the new dosage
The transition to the 7.2 mg dosage requires compliance with a strict therapeutic escalation protocol. Healthcare professionals should prescribe a gradual increase in medication, ensuring that the patient adequately tolerates intermediate concentrations before reaching the maximum permitted level. The body’s adaptation process minimizes the risk of rejection and controls the intensity of adverse reactions during the first weeks of use. Individual clinical assessment determines the exact moment for drug load progression.
The main indication for the higher dose is concentrated in cases where the patient reaches a plateau in weight loss. The metabolic phenomenon occurs when the body adapts to the standard dosage of 2.4 mg, interrupting the reduction in body mass index even with diet and exercise maintenance. The introduction of the 7.2 mg load reactivates the stimulus in the brain receptors responsible for regulating appetite and the feeling of satiety. Dosage adjustment offers a non-surgical alternative for the long-term management of chronic obesity.
The delivery mechanism of Poviztra maintains the format of pre-filled injectable pens designed for subcutaneous use once a week. The device facilitates self-administration by the patient in a home environment, following the instructions provided in the doctor’s office. The technology used in the injection system guarantees the precise release of the exact amount of the active ingredient, avoiding dosage errors. The glycemic control provided by semaglutide also benefits patients who have insulin resistance or pre-diabetes associated with being overweight.
Estratégia commercial and positioning in the Brazilian market
The commercial alliance between Novo Nordisk and Eurofarma establishes Poviztra as a treatment option with a more competitive price compared to direct competitors. The pricing strategy seeks to democratize access to modern therapies against obesity, reaching a larger portion of the population that depends on their own financing to purchase the medication. Large-scale production and distribution optimize logistical costs and directly reflect on the final value passed on to the consumer in pharmacy chains throughout the country.
The impact of the approval of the 7.2 mg dose moves the pharmaceutical sector and generates expectations about the future incorporation of similar treatments in Sistema Único and Saúde. Atualmente, the acquisition of semaglutide for weight loss occurs predominantly on the private market or through supplementary health plans, depending on the specific contractual coverage of each operator. Especialistas in public health monitor price developments and stock availability to assess the feasibility of free distribution policies in cases of morbid obesity with imminent cardiovascular risk.
Diretrizes usage and treatment specifications
The release of Anvisa establishes clear rules for the sale and safe use of the medicine in the national territory. Pharmacies and drugstores must follow strict storage and dispensing standards, ensuring the integrity of the biological product. Compliance with regulatory requirements protects the consumer and ensures the effectiveness of the treatment prescribed by medical specialists.
- Poviztra maintains exactly the same semaglutide molecule present in the Wegovy medicine.
- Progression to 7.2 mg occurs exclusively after confirmation of gastric tolerance in the initial stages.
- The delivery system uses ultra-thin disposable needles to minimize discomfort during injection.
- Dispensing at the pharmacy counter requires the presentation and retention of the special control white medical prescription.
- The indication covers adults with Índice of Massa Corporal equal to or greater than 30, or from 27 with associated diseases.
The shelf supply schedule with the new 7.2 mg presentation depends on the manufacturers’ distribution logistics after publication on Diário Oficial. Retail chains prepare the necessary refrigeration infrastructure to receive updated batches, as semaglutide requires temperature-controlled storage before first use. The transition of stocks will occur gradually in the country’s main capitals and metropolitan regions.
Resultados Clinical and Adverse Effect Monitoring
The scientific rationale for approval of the higher dose is based on long-term randomized clinical trials. Studies have shown that administration of 7.2 mg of semaglutide results in a significantly greater percentage of total weight loss compared to dosing of 2.4 mg. Research participants maintained their weight loss trajectory for prolonged periods, reducing inflammatory markers and improving their blood lipid profile. The proven efficacy consolidates the substance as one of the main pharmacological tools today.
Increasing the concentration of the active ingredient increases the incidence of adverse reactions in the gastrointestinal tract. The most frequent reports include episodes of nausea, vomiting, diarrhea, constipation and abdominal pain, especially in the days immediately following the injection. Clinical data indicate that the intensity of symptoms tends to progressively decrease as the body develops tolerance to the medication. Prophylactic management with portioned meals and adequate hydration helps to mitigate the discomfort reported by patients.
Pacientes with a prior history of acute pancreatitis, gallbladder disease, or severe renal disorders require intensive laboratory monitoring during therapy. The responsible physician must evaluate pancreatic and liver function through periodic blood tests to detect any silent changes. The medication leaflet warns about the need to immediately discontinue use in case of severe and persistent abdominal pain, directing the individual to emergency hospital care.
Importância of changing habits on the effectiveness of the medication
Pharmacological intervention acts as a facilitator of the weight loss process, but does not replace the need for structural changes in lifestyle. Appetite suppression induced by semaglutide creates a window of opportunity for the patient to adopt more nutritious food choices and establish a physical exercise routine. The lack of engagement in healthy practices compromises long-term weight maintenance and increases the likelihood of weight regain after the eventual suspension of drug treatment.
Multidisciplinary monitoring, involving endocrinologists, nutritionists, psychologists and physical education professionals, enhances the results of the 7.2 mg dosage. The integrated approach treats obesity as a chronic and multifactorial disease, addressing metabolic, behavioral and emotional aspects. The release from the regulatory agency aligns Brasil with the most recent international guidelines, offering a robust therapeutic tool to face one of the biggest challenges in contemporary medicine.






